InsiderTrades

Form 4 for YCBD cbdMD, Inc.

Accepted 2022-04-19 00:00:00 ET · period of report 2022-03-11 · accession 0001654954-22-005145 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-04-19 2022-03-11 YCBD Ghiloni Peter J. Dir A - Grant $0.00 +5,000 310.0K +2% $0
D 2022-04-19 2022-03-11 YCBD Ghiloni Peter J. Dir A - Grant — +30.0K 30.0K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-11 A A 5,000 $0.00 310,000 D — — (F1) Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.
2 Derivative Stock Options (Right to Buy) 2022-03-11 A A 30,000 — 30,000 D $0.82 · 2022-03-11 to 2027-03-11 30,000 Common Stock (F2) The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested. (F3) Not applicable.